Skip to main content
Top
Published in: Journal of Infection and Chemotherapy 4/2013

01-08-2013 | Original Article

Effects of slow-releasing colistin microspheres on endotoxin-induced sepsis

Authors: Yuta Nanjo, Yoshikazu Ishii, Soichiro Kimura, Toshiro Fukami, Masahiro Mizoguchi, Toyofumi Suzuki, Kazuo Tomono, Yoshikiyo Akasaka, Toshiharu Ishii, Kazuhisa Takahashi, Kazuhiro Tateda, Keizo Yamaguchi

Published in: Journal of Infection and Chemotherapy | Issue 4/2013

Login to get access

Abstract

Lipopolysaccharide (LPS) is a major contributing factor to endotoxic shock. Colistin specifically binds to LPS. However, it has the disadvantages that adverse reactions are common and it has a short half-life. To overcome these disadvantages, we prepared slow-releasing colistin microspheres and examined the efficacy of these colistin microspheres in a mouse model of endotoxin-induced sepsis. We prepared the colistin microspheres using poly-lactic-co-glycolic acid. For acute toxicity investigations, mice were overdosed with colistin sulfate or colistin microspheres. The group administered with colistin microspheres was associated with less acute toxicity and fewer nephrotoxic changes on histopathological examination compared to the group administered with colistin sulfate alone. For pharmacokinetic analysis, mice were subcutaneously administered with colistin microspheres or colistin sulfate alone. The plasma concentration of colistin was higher in the colistin microspheres group than in the colistin sulfate group at 12 and 24 h after administration. Moreover, mice were intraperitoneally injected with LPS and then immediately subcutaneously administered with blank microspheres, colistin microspheres or colistin sulfate alone. The levels of endotoxin in the sera and cytokine in the spleens were then measured. A significant reduction in the serum endotoxin level in the colistin microspheres group was observed at 24 h. The reduced endotoxin levels in the sera were correlated with the lower cytokine levels in the spleens of mice treated with colistin microspheres. Our results suggest that the use of colistin microspheres may help to maintain a higher colistin concentration in blood, reduce the levels of endotoxin and cytokines in endotoxin-induced sepsis, and lead to decreased toxicity.
Literature
1.
go back to reference Vincent JL. Clinical sepsis and septic shock—definition, diagnosis and management principles. Langenbecks Arch Surg. 2008;393:817–24.PubMedCrossRef Vincent JL. Clinical sepsis and septic shock—definition, diagnosis and management principles. Langenbecks Arch Surg. 2008;393:817–24.PubMedCrossRef
2.
go back to reference Alkharfy KM, Al-Daghri NM, Al-Attas OS, Alokail MS. The protective effect of thymoquinone against sepsis syndrome morbidity and mortality in mice. Int Immunopharmacol. 2011;11:250–4.PubMedCrossRef Alkharfy KM, Al-Daghri NM, Al-Attas OS, Alokail MS. The protective effect of thymoquinone against sepsis syndrome morbidity and mortality in mice. Int Immunopharmacol. 2011;11:250–4.PubMedCrossRef
4.
go back to reference Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54.PubMedCrossRef Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54.PubMedCrossRef
5.
go back to reference Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167:695–701.PubMedCrossRef Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med. 2003;167:695–701.PubMedCrossRef
6.
go back to reference Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47.PubMedCrossRef Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, et al. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care. 2007;11:R47.PubMedCrossRef
7.
go back to reference Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K. Lipopolysaccharide-induced lethality and cytokine production in aged mice. Infect Immun. 1996;64:769–74.PubMed Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K. Lipopolysaccharide-induced lethality and cytokine production in aged mice. Infect Immun. 1996;64:769–74.PubMed
8.
go back to reference Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2003;7:108–14.PubMedCrossRef Shoji H. Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial. 2003;7:108–14.PubMedCrossRef
9.
go back to reference Davies B, Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis. 2011;11:65–71.PubMedCrossRef Davies B, Cohen J. Endotoxin removal devices for the treatment of sepsis and septic shock. Lancet Infect Dis. 2011;11:65–71.PubMedCrossRef
11.
go back to reference Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.PubMedCrossRef Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA. 2009;301:2445–52.PubMedCrossRef
12.
go back to reference Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190:527–34.PubMedCrossRef Marshall JC, Foster D, Vincent JL, Cook DJ, Cohen J, Dellinger RP, et al. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis. 2004;190:527–34.PubMedCrossRef
13.
14.
go back to reference From AH, Fong JS, Good RA. Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs. Infect Immun. 1979;23:660–4.PubMed From AH, Fong JS, Good RA. Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs. Infect Immun. 1979;23:660–4.PubMed
15.
go back to reference Rifkind D. Prevention by polymyxin B of endotoxin lethality in mice. J Bacteriol. 1967;93:1463–4.PubMed Rifkind D. Prevention by polymyxin B of endotoxin lethality in mice. J Bacteriol. 1967;93:1463–4.PubMed
16.
go back to reference Rifkind D, Palmer JD. Neutralization of endotoxin toxicity in chick embryos by antibiotics. J Bacteriol. 1966;92:815–9.PubMed Rifkind D, Palmer JD. Neutralization of endotoxin toxicity in chick embryos by antibiotics. J Bacteriol. 1966;92:815–9.PubMed
17.
go back to reference Hughes B, Madan BR, Parratt JR. Sulphate protects cats against the haemodynamic and metabolic effects of E. coli endotoxin. Br J Pharmacol. 1981;74:701–7.PubMedCrossRef Hughes B, Madan BR, Parratt JR. Sulphate protects cats against the haemodynamic and metabolic effects of E. coli endotoxin. Br J Pharmacol. 1981;74:701–7.PubMedCrossRef
18.
go back to reference Hanasawa K, Tani T, Oka T, Yoshioka T, Endo Y, Horisawa M, et al. A new treatment for endotoxemia with direct hemoperfusion by polymyxin immobilized fiber. 1984. Ther Apher. 2000;4:142–5.PubMedCrossRef Hanasawa K, Tani T, Oka T, Yoshioka T, Endo Y, Horisawa M, et al. A new treatment for endotoxemia with direct hemoperfusion by polymyxin immobilized fiber. 1984. Ther Apher. 2000;4:142–5.PubMedCrossRef
19.
go back to reference Bannatyne RM, Cheung R. Protective effect of polymyxin B sulfate in experimental enterobacterial infection in mice. Can J Microbiol. 1979;25:995–8.PubMedCrossRef Bannatyne RM, Cheung R. Protective effect of polymyxin B sulfate in experimental enterobacterial infection in mice. Can J Microbiol. 1979;25:995–8.PubMedCrossRef
20.
go back to reference Reed MD, Stern RC, O’Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001;41:645–54.PubMedCrossRef Reed MD, Stern RC, O’Riordan MA, Blumer JL. The pharmacokinetics of colistin in patients with cystic fibrosis. J Clin Pharmacol. 2001;41:645–54.PubMedCrossRef
21.
go back to reference Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007;5:811–21.PubMedCrossRef Kwa A, Kasiakou SK, Tam VH, Falagas ME. Polymyxin B: similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007;5:811–21.PubMedCrossRef
22.
go back to reference Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004;53:837–40.PubMedCrossRef Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother. 2004;53:837–40.PubMedCrossRef
23.
go back to reference Institute CaLS. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement. Wayne: CLSI; 2011 (M100-S21). Institute CaLS. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement. Wayne: CLSI; 2011 (M100-S21).
24.
go back to reference Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull (Tokyo). 1988;36:1095–103.CrossRef Ogawa Y, Yamamoto M, Okada H, Yashiki T, Shimamoto T. A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid. Chem Pharm Bull (Tokyo). 1988;36:1095–103.CrossRef
25.
go back to reference Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;761:167–75.PubMedCrossRef Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001;761:167–75.PubMedCrossRef
26.
go back to reference Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;63:534–42.PubMedCrossRef Aoki N, Tateda K, Kikuchi Y, Kimura S, Miyazaki C, Ishii Y, et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2009;63:534–42.PubMedCrossRef
27.
go back to reference Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2007;51:446–52.PubMedCrossRef Watanabe R, Matsumoto T, Sano G, Ishii Y, Tateda K, Sumiyama Y, et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob Agents Chemother. 2007;51:446–52.PubMedCrossRef
28.
go back to reference Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Annu Rev Immunol. 1992;10:267–93.PubMedCrossRef Cohen JJ, Duke RC, Fadok VA, Sellins KS. Apoptosis and programmed cell death in immunity. Annu Rev Immunol. 1992;10:267–93.PubMedCrossRef
29.
go back to reference Van Leeuwen PA, Boermeester MA, Houdijk AP, Ferwerda CC, Cuesta MA, Meyer S, et al. Clinical significance of translocation. Gut. 1994;35:S28–34.PubMedCrossRef Van Leeuwen PA, Boermeester MA, Houdijk AP, Ferwerda CC, Cuesta MA, Meyer S, et al. Clinical significance of translocation. Gut. 1994;35:S28–34.PubMedCrossRef
30.
go back to reference Buttenschoen K, Radermacher P, Bracht H. Endotoxin elimination in sepsis: physiology and therapeutic application. Langenbecks Arch Surg. 2010;395:597–605.PubMedCrossRef Buttenschoen K, Radermacher P, Bracht H. Endotoxin elimination in sepsis: physiology and therapeutic application. Langenbecks Arch Surg. 2010;395:597–605.PubMedCrossRef
31.
go back to reference Zhong M, Kadota Y, Shimizu Y, Gohda E. Induction of cytolytic activity and interferon-gamma production in murine natural killer cells by polymyxins B and E. Int Immunopharmacol. 2008;8:508–13.PubMedCrossRef Zhong M, Kadota Y, Shimizu Y, Gohda E. Induction of cytolytic activity and interferon-gamma production in murine natural killer cells by polymyxins B and E. Int Immunopharmacol. 2008;8:508–13.PubMedCrossRef
32.
go back to reference Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.PubMedCrossRef Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care. 2006;10:R27.PubMedCrossRef
33.
go back to reference Ozyilmaz E, Ebinc FA, Derici U, Gulbahar O, Goktas G, Elmas C, et al. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med. 2011;37:141–6.PubMedCrossRef Ozyilmaz E, Ebinc FA, Derici U, Gulbahar O, Goktas G, Elmas C, et al. Could nephrotoxicity due to colistin be ameliorated with the use of N-acetylcysteine? Intensive Care Med. 2011;37:141–6.PubMedCrossRef
34.
go back to reference Mendes CA, Burdmann EA. Polymyxins—review with emphasis on nephrotoxicity. Rev Assoc Med Bras. 2009;55:752–9.PubMedCrossRef Mendes CA, Burdmann EA. Polymyxins—review with emphasis on nephrotoxicity. Rev Assoc Med Bras. 2009;55:752–9.PubMedCrossRef
35.
go back to reference Moyer JH, Mills LC, Yow EM. Toxicity of polymyxin B. I. Animal studies with particular reference to evaluation of renal function. AMA Arch Intern Med. 1953;92:238–47.PubMedCrossRef Moyer JH, Mills LC, Yow EM. Toxicity of polymyxin B. I. Animal studies with particular reference to evaluation of renal function. AMA Arch Intern Med. 1953;92:238–47.PubMedCrossRef
36.
go back to reference Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis. 2008;13:11–32.PubMedCrossRef Servais H, Ortiz A, Devuyst O, Denamur S, Tulkens PM, Mingeot-Leclercq MP. Renal cell apoptosis induced by nephrotoxic drugs: cellular and molecular mechanisms and potential approaches to modulation. Apoptosis. 2008;13:11–32.PubMedCrossRef
37.
go back to reference McMillan FH, Pattison IC. Sodium colistimethate. I. Dissociations of aminomethanesulfonates in aqueous solution. J Pharm Sci. 1969;58:730–7.PubMedCrossRef McMillan FH, Pattison IC. Sodium colistimethate. I. Dissociations of aminomethanesulfonates in aqueous solution. J Pharm Sci. 1969;58:730–7.PubMedCrossRef
38.
go back to reference Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45:781–5.PubMedCrossRef Li J, Turnidge J, Milne R, Nation RL, Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother. 2001;45:781–5.PubMedCrossRef
39.
go back to reference Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother. 2003;47:1364–70.PubMedCrossRef Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K. Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography. Antimicrob Agents Chemother. 2003;47:1364–70.PubMedCrossRef
Metadata
Title
Effects of slow-releasing colistin microspheres on endotoxin-induced sepsis
Authors
Yuta Nanjo
Yoshikazu Ishii
Soichiro Kimura
Toshiro Fukami
Masahiro Mizoguchi
Toyofumi Suzuki
Kazuo Tomono
Yoshikiyo Akasaka
Toshiharu Ishii
Kazuhisa Takahashi
Kazuhiro Tateda
Keizo Yamaguchi
Publication date
01-08-2013
Publisher
Springer Japan
Published in
Journal of Infection and Chemotherapy / Issue 4/2013
Print ISSN: 1341-321X
Electronic ISSN: 1437-7780
DOI
https://doi.org/10.1007/s10156-012-0544-y

Other articles of this Issue 4/2013

Journal of Infection and Chemotherapy 4/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine